Novavax has undertaken a strategic transition since 2023, moving away from ambitions of operating as a fully integrated commercial vaccine company toward a leaner structure centered on partnerships. This shift follows the company’s reassessment of its position in a competitive vaccine market that evolved after the COVID-19 pandemic.
During the pandemic, Novavax sought to establish itself alongside larger vaccine developers. It achieved a degree of that goal when its protein-based COVID-19 vaccine, Nuvaxovid, received emergency use authorization in 2022 and full approval from the U.S. Food and Drug Administration in May 2025. However, entering the market later than competitors and facing declining demand made sustaining a large commercial infrastructure financially challenging.
The company subsequently restructured under CEO John Jacobs in 2023, initially reducing research and development and other costs to prioritize its COVID-19 program. By 2024, Novavax had shifted further toward a partnership-focused model, supported by a collaboration with Sanofi for Nuvaxovid and potential combination vaccines. This approach allowed the company to rely on partners with established commercial capabilities while concentrating internally on its scientific platform.
Central to this strategy is Matrix-M, a saponin-based vaccine adjuvant designed to enhance immune responses. Novavax is positioning Matrix-M as a licensable technology for other pharmaceutical companies. The adjuvant is already used in Nuvaxovid and in a malaria vaccine developed by the University of Oxford and the Serum Institute of India, and it has been administered to tens of millions of individuals.
The partnership strategy began generating financial outcomes in early 2026 when Pfizer agreed to pay $30 million upfront, with potential milestone payments of up to $500 million, for the use of Matrix-M in two programs. In addition, four other pharmaceutical companies have entered material transfer agreements to evaluate the adjuvant before committing to licensing arrangements.
According to Silvia Taylor, Novavax’s chief corporate affairs officer and head of Sweden operations, expanding access through partnerships is central to the company’s revised direction. “The best way to increase access to our technology platform is to put it in the hands of partners, right?” she said, describing the approach as an amplification strategy.
The company’s financial structure has changed significantly alongside this shift. In 2025, cost of sales decreased to $73 million from $203 million in 2024. Non-GAAP research and development expenses declined by 33% year over year, supported in part by reimbursement from Sanofi, while selling, general, and administrative expenses fell by 53% to $157 million. Novavax has set targets to further reduce combined R&D and SG&A expenses to $325 million in 2026, $225 million in 2027, and $200 million in 2028.
Although its commercial operations have been scaled back, Novavax continues to maintain research and strategy teams. The R&D group is focused on exploring new applications for Matrix-M, including potential compatibility with mRNA technologies, alternative formulations such as dry powders, and next-generation improvements. Interest has also emerged from potential partners in oncology, though development in that area remains at an early stage.
The company retains limited internal vaccine development efforts, including a preclinical candidate for C. difficile that could enter clinical trials in 2027 with the intention of partnering later. Meanwhile, Novavax has paused its own COVID-flu combination vaccine program, anticipating that a partner would lead any late-stage development.
Sanofi, rather than advancing Novavax’s combination candidate, is combining Nuvaxovid with its own influenza vaccines and plans to progress into phase 3 trials. Other large pharmaceutical companies are also pursuing similar combination vaccine approaches.
While Novavax remains open to potential acquisition offers as a public company, its leadership has indicated that current conditions may not reflect the company’s full valuation. In the near term, the company is prioritizing royalty-based revenue from partnerships, which it considers a primary source of long-term financial returns once partnered products reach the market.
Matrix-M: The Core of Novavax’s Future
The Matrix-M adjuvant is a key innovation that enhances immune response and improves vaccine efficacy. Novavax plans to license this technology to partners, creating new revenue streams.
Benefits of Matrix-M include:
- Stronger immune response with lower antigen doses
- Broad applicability across multiple vaccines
- Proven performance in clinical trials
By centering its strategy on Matrix-M, Novavax positions itself as a technology leader rather than just a vaccine manufacturer.
Partnership Opportunities for Novavax
The new model opens doors for Novavax to collaborate with:
- Global pharmaceutical companies
- Biotech startups
- Government and research institutions
Through these partnerships, Novavax can accelerate innovation while sharing risks and costs.
